{"id":116661,"date":"2024-01-03T12:56:20","date_gmt":"2024-01-03T07:26:20","guid":{"rendered":"https:\/\/tradebrains.in\/features\/?p=116661"},"modified":"2024-01-03T13:32:10","modified_gmt":"2024-01-03T08:02:10","slug":"midcap-stock-in-green-after-it-launches-an-anti%e2%80%90diabetic-drug-that-would-cut-down-70-of-therapy-cost","status":"publish","type":"post","link":"https:\/\/tradebrains.in\/features\/midcap-stock-in-green-after-it-launches-an-anti%e2%80%90diabetic-drug-that-would-cut-down-70-of-therapy-cost\/","title":{"rendered":"Midcap stock in green after it launches an anti\u2010diabetic drug that would cut down 70% of therapy cost\u00a0"},"content":{"rendered":"<div class=\"trade-content_2\" style=\"margin-left: auto;margin-right: auto;text-align: center;\" id=\"trade-412258140\"><p><a href=\"https:\/\/tradebrains.in\/get\/telegram\/\"><img decoding=\"async\" class=\"alignnone wp-image-101992\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/01\/telegram-channel-300x119.png\" alt=\"\" width=\"148\" height=\"59\" \/><\/a> <a href=\"https:\/\/news.google.com\/publications\/CAAqBwgKMN3Epgswxc--Aw?hl=en-IN&amp;gl=IN&amp;ceid=IN%3Aen\"><img decoding=\"async\" class=\"alignnone wp-image-123430\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-300x82.png\" alt=\"follow-on-google-news\" width=\"222\" height=\"61\" srcset=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-300x82.png 300w, https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-150x41.png 150w, https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news.png 468w\" sizes=\"(max-width: 222px) 100vw, 222px\" \/><\/a><\/p>\n<\/div><p>Multibagger pharma stock that has a presence across Branded pharmaceuticals, Generics, and OTC segments in green after it becomes the first company to launch a Biosimilar of a Popular Anti\u2010Diabetic Drug in India that would cut down the therapy cost by 70 percent.&nbsp;<\/p><div class=\"trade-content_7\" style=\"margin-left: auto;margin-right: auto;text-align: center;\" id=\"trade-1473912258\"><!-- Composite Start --> \r\n <div id=\"M923760ScriptRootC1549812\"> \r\n <\/div> \r\n <script src=\"https:\/\/jsc.mgid.com\/t\/r\/tradebrains.in.1549812.js\" async> \r\n <\/script> \r\n <!-- Composite End --><\/div><p>At 11:25 a.m the shares of Glenmark Pharmaceuticals Limited were trading at Rs. 892.60, up 0.63 percent from its previous day\u2019s close price of Rs. 888.80 and its market capitalization is Rs. 25,172 Crores. It has delivered multi-bagger returns of 106 percent in a year.&nbsp;<\/p><p>Glenmark Pharmaceuticals Limited became the first company to launch a Biosimilar of a Popular Anti\u2010Diabetic Drug, Liraglutide. It was launched under the brand name Lirafit which is indicated for improving glycemic control in adult patients with type 2 diabetes mellitus.&nbsp;<\/p><p>Lirafit will sharply lower the daily cost of therapy by around 70 percent to around Rs100, making the drug more accessible to a larger number of patients with type 2 diabetes mellitus in the country.&nbsp;<\/p><div class=\"trade-content_5\" id=\"trade-3055385249\"><script async src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-4023722985638610\"\r\n     crossorigin=\"anonymous\"><\/script>\r\n<!-- in_content_2_news -->\r\n<ins class=\"adsbygoogle\"\r\n     style=\"display:block\"\r\n     data-ad-client=\"ca-pub-4023722985638610\"\r\n     data-ad-slot=\"7925020301\"\r\n     data-ad-format=\"auto\"\r\n     data-full-width-responsive=\"true\"><\/ins>\r\n<script>\r\n     (adsbygoogle = window.adsbygoogle || []).push({});\r\n<\/script><\/div><p>The company\u2019s revenue from operations grew 5.57 percent from Rs. 12,304.9 Crores in FY22 to Rs. 12,990.11 Crores in FY23, accompanied by profits of Rs. 941.71 Crores to Rs. 297.25 Crores.&nbsp;<\/p><p>It has reported a return on equity (ROE) of 4.07 percent and a return on capital employed (ROCE) of 9.17 percent, it is making decent returns on its equity and capital employed, as there has been no growth in its profitability over the years.&nbsp;<\/p><p>Glenmark Pharmaceuticals Limited is a research\u2010led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments, with a focus on therapeutic areas of respiratory, dermatology, and oncology.&nbsp;<\/p><blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\"><p><strong>Written by: Bharath K.S<\/strong><\/p><\/blockquote><h4 class=\"wp-block-heading\" id=\"h-disclaimer\"><strong>Disclaimer<\/strong><\/h4><p><strong>The views and investment tips expressed by investment experts\/broking houses\/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.<\/strong><\/p><div class=\"trade-after-content\" id=\"trade-2147268500\"><div id=\"taboola-below-article-thumbnails\"><\/div>\r\n<script type=\"text\/javascript\">\r\n  window._taboola = window._taboola || [];\r\n  _taboola.push({\r\n    mode: 'alternating-thumbnails-a',\r\n    container: 'taboola-below-article-thumbnails',\r\n    placement: 'Below Article Thumbnails',\r\n    target_type: 'mix'\r\n  });\r\n<\/script>\r\n<script type=\"text\/javascript\">\r\n  window._taboola = window._taboola || [];\r\n  _taboola.push({flush: true});\r\n<\/script><\/div>","protected":false},"excerpt":{"rendered":"<p>Multibagger pharma stock that has a presence across Branded pharmaceuticals, Generics, and OTC segments in green after it becomes the first company to launch a Biosimilar of a Popular Anti\u2010Diabetic Drug in India that would cut down the therapy cost by 70 percent.&nbsp; At 11:25 a.m the shares of Glenmark Pharmaceuticals Limited were trading at [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":49884,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[31,13525],"tags":[],"class_list":["post-116661","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-stock-updates"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v20.5 (Yoast SEO v25.0) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Midcap stock in green after it launches an anti\u2010diabetic drug that would cut down 70% of therapy cost\u00a0 - Trade Brains Features<\/title>\n<meta name=\"description\" content=\"Multibagger pharma stock that has a presence across Branded pharmaceuticals, Generics, and OTC segments in green after it becomes the first company to launch a Biosimilar of a Popular Anti\u2010Diabetic Drug in India that would cut down the therapy cost by 70 percent.\u00a0\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/tradebrains.in\/features\/midcap-stock-in-green-after-it-launches-an-anti\u2010diabetic-drug-that-would-cut-down-70-of-therapy-cost\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Midcap stock in green after it launches an anti\u2010diabetic drug that would cut down 70% of therapy cost\u00a0\" \/>\n<meta property=\"og:description\" content=\"Multibagger pharma stock that has a presence across Branded pharmaceuticals, Generics, and OTC segments in green after it becomes the first company to launch a Biosimilar of a Popular Anti\u2010Diabetic Drug in India that would cut down the therapy cost by 70 percent.\u00a0\" \/>\n<meta property=\"og:url\" content=\"https:\/\/tradebrains.in\/features\/midcap-stock-in-green-after-it-launches-an-anti\u2010diabetic-drug-that-would-cut-down-70-of-therapy-cost\/\" \/>\n<meta property=\"og:site_name\" content=\"Trade Brains Features\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/TradeBrainsOfficial\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-01-03T07:26:20+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-01-03T08:02:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/06\/Pharma-1-Cover-Image.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"854\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Trade Brains\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@TradeBrainsGrp\" \/>\n<meta name=\"twitter:site\" content=\"@TradeBrainsGrp\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Trade Brains\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/tradebrains.in\/features\/midcap-stock-in-green-after-it-launches-an-anti%e2%80%90diabetic-drug-that-would-cut-down-70-of-therapy-cost\/\",\"url\":\"https:\/\/tradebrains.in\/features\/midcap-stock-in-green-after-it-launches-an-anti%e2%80%90diabetic-drug-that-would-cut-down-70-of-therapy-cost\/\",\"name\":\"Midcap stock in green after it launches an anti\u2010diabetic drug that would cut down 70% of therapy cost\u00a0 - Trade Brains Features\",\"isPartOf\":{\"@id\":\"https:\/\/tradebrains.in\/features\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/tradebrains.in\/features\/midcap-stock-in-green-after-it-launches-an-anti%e2%80%90diabetic-drug-that-would-cut-down-70-of-therapy-cost\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/tradebrains.in\/features\/midcap-stock-in-green-after-it-launches-an-anti%e2%80%90diabetic-drug-that-would-cut-down-70-of-therapy-cost\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/06\/Pharma-1-Cover-Image.jpg\",\"datePublished\":\"2024-01-03T07:26:20+00:00\",\"dateModified\":\"2024-01-03T08:02:10+00:00\",\"author\":{\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666\"},\"description\":\"Multibagger pharma stock that has a presence across Branded pharmaceuticals, Generics, and OTC segments in green after it becomes the first company to launch a Biosimilar of a Popular Anti\u2010Diabetic Drug in India that would cut down the therapy cost by 70 percent.\u00a0\",\"breadcrumb\":{\"@id\":\"https:\/\/tradebrains.in\/features\/midcap-stock-in-green-after-it-launches-an-anti%e2%80%90diabetic-drug-that-would-cut-down-70-of-therapy-cost\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/tradebrains.in\/features\/midcap-stock-in-green-after-it-launches-an-anti%e2%80%90diabetic-drug-that-would-cut-down-70-of-therapy-cost\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/tradebrains.in\/features\/midcap-stock-in-green-after-it-launches-an-anti%e2%80%90diabetic-drug-that-would-cut-down-70-of-therapy-cost\/#primaryimage\",\"url\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/06\/Pharma-1-Cover-Image.jpg\",\"contentUrl\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/06\/Pharma-1-Cover-Image.jpg\",\"width\":1280,\"height\":854},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/tradebrains.in\/features\/midcap-stock-in-green-after-it-launches-an-anti%e2%80%90diabetic-drug-that-would-cut-down-70-of-therapy-cost\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/tradebrains.in\/features\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Midcap stock in green after it launches an anti\u2010diabetic drug that would cut down 70% of therapy cost\u00a0\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/tradebrains.in\/features\/#website\",\"url\":\"https:\/\/tradebrains.in\/features\/\",\"name\":\"Trade Brains\",\"description\":\"Stock Market NSE\/BSE Latest News\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/tradebrains.in\/features\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666\",\"name\":\"Trade Brains\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g\",\"caption\":\"Trade Brains\"},\"sameAs\":[\"http:\/\/tradebrains.in\/\"],\"url\":\"https:\/\/tradebrains.in\/features\/author\/trade-brains\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Midcap stock in green after it launches an anti\u2010diabetic drug that would cut down 70% of therapy cost\u00a0 - Trade Brains Features","description":"Multibagger pharma stock that has a presence across Branded pharmaceuticals, Generics, and OTC segments in green after it becomes the first company to launch a Biosimilar of a Popular Anti\u2010Diabetic Drug in India that would cut down the therapy cost by 70 percent.\u00a0","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/tradebrains.in\/features\/midcap-stock-in-green-after-it-launches-an-anti\u2010diabetic-drug-that-would-cut-down-70-of-therapy-cost\/","og_locale":"en_US","og_type":"article","og_title":"Midcap stock in green after it launches an anti\u2010diabetic drug that would cut down 70% of therapy cost\u00a0","og_description":"Multibagger pharma stock that has a presence across Branded pharmaceuticals, Generics, and OTC segments in green after it becomes the first company to launch a Biosimilar of a Popular Anti\u2010Diabetic Drug in India that would cut down the therapy cost by 70 percent.\u00a0","og_url":"https:\/\/tradebrains.in\/features\/midcap-stock-in-green-after-it-launches-an-anti\u2010diabetic-drug-that-would-cut-down-70-of-therapy-cost\/","og_site_name":"Trade Brains Features","article_publisher":"https:\/\/www.facebook.com\/TradeBrainsOfficial\/","article_published_time":"2024-01-03T07:26:20+00:00","article_modified_time":"2024-01-03T08:02:10+00:00","og_image":[{"width":1280,"height":854,"url":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/06\/Pharma-1-Cover-Image.jpg","type":"image\/jpeg"}],"author":"Trade Brains","twitter_card":"summary_large_image","twitter_creator":"@TradeBrainsGrp","twitter_site":"@TradeBrainsGrp","twitter_misc":{"Written by":"Trade Brains","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/tradebrains.in\/features\/midcap-stock-in-green-after-it-launches-an-anti%e2%80%90diabetic-drug-that-would-cut-down-70-of-therapy-cost\/","url":"https:\/\/tradebrains.in\/features\/midcap-stock-in-green-after-it-launches-an-anti%e2%80%90diabetic-drug-that-would-cut-down-70-of-therapy-cost\/","name":"Midcap stock in green after it launches an anti\u2010diabetic drug that would cut down 70% of therapy cost\u00a0 - Trade Brains Features","isPartOf":{"@id":"https:\/\/tradebrains.in\/features\/#website"},"primaryImageOfPage":{"@id":"https:\/\/tradebrains.in\/features\/midcap-stock-in-green-after-it-launches-an-anti%e2%80%90diabetic-drug-that-would-cut-down-70-of-therapy-cost\/#primaryimage"},"image":{"@id":"https:\/\/tradebrains.in\/features\/midcap-stock-in-green-after-it-launches-an-anti%e2%80%90diabetic-drug-that-would-cut-down-70-of-therapy-cost\/#primaryimage"},"thumbnailUrl":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/06\/Pharma-1-Cover-Image.jpg","datePublished":"2024-01-03T07:26:20+00:00","dateModified":"2024-01-03T08:02:10+00:00","author":{"@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666"},"description":"Multibagger pharma stock that has a presence across Branded pharmaceuticals, Generics, and OTC segments in green after it becomes the first company to launch a Biosimilar of a Popular Anti\u2010Diabetic Drug in India that would cut down the therapy cost by 70 percent.\u00a0","breadcrumb":{"@id":"https:\/\/tradebrains.in\/features\/midcap-stock-in-green-after-it-launches-an-anti%e2%80%90diabetic-drug-that-would-cut-down-70-of-therapy-cost\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/tradebrains.in\/features\/midcap-stock-in-green-after-it-launches-an-anti%e2%80%90diabetic-drug-that-would-cut-down-70-of-therapy-cost\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tradebrains.in\/features\/midcap-stock-in-green-after-it-launches-an-anti%e2%80%90diabetic-drug-that-would-cut-down-70-of-therapy-cost\/#primaryimage","url":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/06\/Pharma-1-Cover-Image.jpg","contentUrl":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/06\/Pharma-1-Cover-Image.jpg","width":1280,"height":854},{"@type":"BreadcrumbList","@id":"https:\/\/tradebrains.in\/features\/midcap-stock-in-green-after-it-launches-an-anti%e2%80%90diabetic-drug-that-would-cut-down-70-of-therapy-cost\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/tradebrains.in\/features\/"},{"@type":"ListItem","position":2,"name":"Midcap stock in green after it launches an anti\u2010diabetic drug that would cut down 70% of therapy cost\u00a0"}]},{"@type":"WebSite","@id":"https:\/\/tradebrains.in\/features\/#website","url":"https:\/\/tradebrains.in\/features\/","name":"Trade Brains","description":"Stock Market NSE\/BSE Latest News","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/tradebrains.in\/features\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666","name":"Trade Brains","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g","caption":"Trade Brains"},"sameAs":["http:\/\/tradebrains.in\/"],"url":"https:\/\/tradebrains.in\/features\/author\/trade-brains\/"}]}},"_links":{"self":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/116661","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/comments?post=116661"}],"version-history":[{"count":1,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/116661\/revisions"}],"predecessor-version":[{"id":116662,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/116661\/revisions\/116662"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/media\/49884"}],"wp:attachment":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/media?parent=116661"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/categories?post=116661"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/tags?post=116661"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}